

The Fritsma Factor

YOUR INTERACTIVE HEMOSTASIS RESOURCE

Cheat Sheet—August 1, 2022



Welcome to our August 2022 Fritsma Factor Cheat Sheet. We look forward to seeing you at the Thrombosis and Hemostasis Summit of North America [THSNA] August 18–19 in Chicago.

July and August 2022 Quick Questions

Our July 2022 Quick Question asked, "What von Willebrand disease [VWD] subtype is identified using the reduced concentration ristocetin-induced platelet aggregometry [RIPA] test?" Many of the VWD types and subtypes are currently identified by molecular diagnosis, however, the "legacy" phenotypic tests often provide a speedy and inexpensive shortcut. The question attracted 30 respondents, and a [summary](#) is now available on Fritsma Factor.

Our August 2022 Quick Question addresses lupus anticoagulant testing, a member of the standard thrombophilia screening profile. "You test for lupus anticoagulant [LAC] using a low-PL PTT reagent and a hex-phase high-PL mix. The mix results are 10 seconds shorter than the first test. What do you conclude?" The question illustrates the PTT-based LAC test in which the initial test employs a partial thromboplastin reagent with reduced phospholipid [PL] designed to be sensitive to LAC followed by a confirmatory hex-phase high PL reagent meant to neutralize LAC. Please open the [FF home page](#), select your answer in the right-hand column, and [add your comment](#).

Coming Events

Fritsma Factor continues to provide a [link to the three-part "Coag Conversations" webinar](#) featuring **Brandon M. Henry, MD**, entitled "What have we learned about inflammation and thrombosis since the COVID-19 outbreak?" Dr. Henry is a physician scientist and investigative pathologist affiliated with the Cincinnati Children's Hospital Medical Center. The third segment of the series appears August 10, 2022.

The posters presented by our sponsors Precision BioLogic and Affinity Biologicals at the London ISTH meeting are now available from Fritsma Factor. Click here for access:

- [PB1177: Performance of FVIII Deficient Plasma with VWF in the Activity Measurement of FVIII Replacement Products in Plasma Samples Using an OSC Assay](#)
- [PB1183: Performance of a Chromogenic Factor IX Activity Assay in the Recovery of Factor IX Replacement Therapies](#)

When you see George, Precision BioLogic or Affinity Biologicals representatives at THSNA, be sure to tell us about your loyalty to The Fritsma Factor and provide us with your questions or comments.

George A. Fritsma MS, MLS
The Fritsma Factor, Your Interactive Hemostasis Resource
www.fritsmafactor.com, george@fritsmafactor.com